[
    [
        {
            "time": "2018-01-02",
            "original_text": "Look at Novo Nordisk’s Biopharmaceuticals",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Biopharmaceuticals"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Look at Novo Nordisk’s Biopharmaceuticals",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "NVO’s Victoza and Ozempic Could See Steady Growth in 2018",
            "features": {
                "keywords": [
                    "NVO",
                    "Victoza",
                    "Ozempic",
                    "Steady Growth"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "NVO’s Victoza and Ozempic Could See Steady Growth in 2018",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Free Technical Reports on Novavax and Three Additional Biotech Equities",
            "features": {
                "keywords": [
                    "Technical Reports",
                    "Novavax",
                    "Biotech Equities"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Free Technical Reports on Novavax and Three Additional Biotech Equities",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]